Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;55(9):1099-1115.
doi: 10.1111/apt.16831. Epub 2022 Mar 2.

Review article: current and emerging therapies for the management of cirrhosis and its complications

Elliot B Tapper  1 , Nneka N Ufere  2 , Daniel Q Huang  3   4   5 , Rohit Loomba  5
Affiliations
Review

Review article: current and emerging therapies for the management of cirrhosis and its complications

Elliot B Tapper et al. Aliment Pharmacol Ther. 2022 May.

Abstract

Background: Cirrhosis is increasingly common and morbid. Optimal utilisation of therapeutic strategies to prevent and control the complications of cirrhosis are central to improving clinical and patient-reported outcomes.

Methods: We conducted a narrative review of the literature focusing on the most recent advances.

Results: We review the aetiology-focused therapies that can prevent cirrhosis and its complications. These include anti-viral therapies, psychopharmacological therapy for alcohol-use disorder, and the current landscape of clinical trials for non-alcoholic steatohepatitis. We review the current standard of care and latest developments in the management of hepatic encephalopathy (HE), ascites and hepatorenal syndrome. We evaluate the promise and drawbacks of chemopreventative therapies that have been examined in trials and observational studies which may reduce the risk of hepatocellular carcinoma and cirrhosis complications. Finally, we examine the therapies which address the non-pain symptoms of cirrhosis including pruritis, muscle cramps, sexual dysfunction and fatigue.

Conclusion: The improvement of clinical and patient-reported outcomes for patients with cirrhosis is possible by applying evidence-based pharmacotherapeutic approaches to the prevention and treatment of cirrhosis complications.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Aetiology directed therapies to prevent decompensations of cirrhosis. Patients with cirrhosis may have multiple disease aetiologies. Efforts to address alcohol use, lifestyle change and elimination or control of viral hepatitis are essential
FIGURE 2
FIGURE 2
The physiological basis of therapies to prevent and manage cirrhosis complications. AKI, acute kidney injury; BCAA, branch‐chain amino acids; HRS, hepatorenal syndrome; US, United States
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:122‐128. - PubMed
    1. Mellinger JL, Shedden K, Winder GS, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68:872‐882. - PubMed
    1. Asrani SK, Kouznetsova M, Ogola G, et al. Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004‐2013. Gastroenterology. 2018;155:719‐729. e4. - PubMed
    1. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999‐2016: observational study. BMJ. 2018;362:k2817. - PMC - PubMed
    1. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all‐cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584‐2593. - PubMed

Publication types